Local News

• AstraZeneca and POZEN announce PN 400 Phase III study results  AstraZeneca and POZEN, co-development partner for the investigational compound PN 400, announced results from two Phase III studies, PN 400-301 and PN 400-302 comparing PN 400 to enteric-coated naproxen 500 mg. These studies were conducted by POZEN under an agreed Special FDA Protocol Assessment.
  AstraZeneca December 03, 2008  
• Bionovo announces development plans for menopausal hot flash drug candidate  Bionovo announced that the FDA has reviewed the company's manufacturing and control process descriptions (CMC), and has provided guidance on how Bionovo can move forward with the development of Menerba (formerly named MF101) for menopausal hot flashes.
  Bionovo, Inc. December 03, 2008  
• Cell Genesys amends and extends "modified Dutch Auction" tender offer to $80 million  Cell Genesys has amended and extended its "Modified Dutch Auction" tender offer for a portion of its outstanding 3.125% Convertible Senior Notes due 2011. Under the "Modified Dutch Auction" procedure, Cell Genesys will now offer to purchase, for cash, up to $80 million aggregate principal amount.
  Cell Genesys, Inc. December 03, 2008  
• Covidien's Hi-Lo Evac(TM) endotracheal tube selected for comparative innovation program  Covidien announced that its Hi-Lo Evac(TM) endotracheal tube was named part of Premier Healthcare Alliance's QUEST Comparative Innovation Program. The Hi-Lo Evac tube facilitates continuous aspiration of subglottic secretions to reduce ventilator-associated pneumonia.
  Covidien December 03, 2008  
• Isis Announces survival advantage in prostate cancer study  Isis announced that OncoGenex Pharmaceuticals provided positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone compared to docetaxel and prednisone alone for first-line treatment of metastatic castrate resistant prostate cancer.
  Isis Pharmaceuticals, Inc. December 03, 2008  
• CytRx unveils clinical development plan for pipeline assets  CytRx Corporation unveiled its corporate strategy to focus its internal resources on the clinical development of oncology drug candidates tamibarotene and INNO-206, which the Company believes offer the greatest mix of near-term and medium-term revenue potential among its clinical assets.
  CytRx Corporation December 03, 2008  
• Wyeth submits European marketing authorization application for its 13-Valent Vaccine  Wyeth Pharmaceuticals announced that it has submitted a marketing authorization application to the European Medicines Agency for approval to market its investigational 13-valent pneumococcal conjugate vaccine (PCV13) for infants and young children.
  Wyeth Pharmaceuticals December 03, 2008  
• Medtronic receives FDA approval of Sprint Quattro Secure S Single Coil Defibrillation Lead  Medtronic announced U.S. FDA approval of the Medtronic Sprint Quattro Secure® S single coil defibrillation lead (Model 6935) for use with implantable defibrillators in patients at risk for dangerous tachyarrhythmias (fast heartbeats) and sudden cardiac arrest.
  Medtronic, Inc. December 03, 2008  
• Forest Laboratories responds to unsolicited mini-tender offer  Forest Laboratories has been notified of an unsolicited mini-tender offer by TRC Capital Corporation of Toronto, Canada, a private investment company. Forest Laboratories has received a copy of the tender offer to purchase up to 3.0 million outstanding shares of the company's common stock.
  Forest Laboratories, Inc. December 03, 2008  
• Cell Genesys and Takeda terminate collaboration agreement for GVAX Immunotherapy  Cell Genesys and Takeda Pharmaceutical have mutually agreed to suspend the further development of GVAX immunotherapy for prostate cancer and that Takeda has ended the collaboration agreement with Cell Genesys for the development and commercialization of the product.
  Cell Genesys, Inc. December 03, 2008  

   (next 10 articles)